Avita Medical Inc. (RCEL) Stock: Price, Forecast & Analyst Target
Avita Medical Inc. (RCEL) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $15.99 (-4.99%), as of the Nov 19, 2026 trading session; market cap $507M.
Educational signal · not a buy or sell recommendation · How to read this
Avita Medical Inc. · RCEL · NASDAQ
AVITA Medical Inc. is a commercial-stage regenerative tissue company focused on unmet medical needs in burn injuries, trauma, chronic wounds, and dermatological applications. Their lead product, the RECELL System, allows healthcare professionals to create Spray-On Skin cells from a patient's own skin for burn treatment.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Avita Medical (RCEL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z -8.68 · Piotroski F 4
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 24 | Weak | |
| 25 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $15.99 | |
| Change on the day | -4.99% | |
| 52-week range | $3.22 – $18.43 | |
| Market capitalisation | $507M | — |
| Shares traded on the day | 362.5K |
Price & events
Other perspectives
Council score for Avita Medical (RCEL): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Avita Medical (RCEL), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Avita Medical Inc. (RCEL) is listed on NASDAQ. It employs 226 people and is led by Cary G. Vance. The market values it at $507M.
What do the latest results show for Avita Medical (RCEL)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $17M | -$13M | -$0.46 (diluted) |
| Q4 FY2025 | $18M | -$12M | -$0.38 (diluted) |
| Q1 FY2026 | $19M | -$11M | -$0.35 (diluted) |
| Q2 FY2026 | $22M | -$8M | -$0.25 (diluted) |
What are the financial strengths and risks for Avita Medical (RCEL)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -8.68 · Piotroski F 4. Trailing ratios: ROA -32.5% · current ratio 1.20.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -8.68 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Avita Medical (RCEL)?
Short answer · as of
Current published price targets run low $11.00 · high $20.00 · consensus $14.33 · median $12.00 against a quoted price of $15.99 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Avita Medical compare with its peers?
Short answer
Avita Medical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $19.24 Nov 19, 2026 | $669M | 94 5-pillar Nov 18, 2026 | |
| $12.88 Nov 18, 2026 | $741M | 92 5-pillar Nov 18, 2026 | |
| $26.42 Nov 18, 2026 | $592M | 90 5-pillar Nov 18, 2026 | |
| $8.61 Nov 19, 2026 | $326M | 88 5-pillar Nov 18, 2026 | |
| $8.98 Nov 18, 2026 | $361M | 87 5-pillar Nov 18, 2026 | |
| $10.62 Nov 18, 2026 | $727M | 79 5-pillar Nov 18, 2026 | |
| $18.15 Nov 18, 2026 | $771M | 62 5-pillar Nov 18, 2026 | |
| $32.51 Nov 19, 2026 | $849M | 37 5-pillar Nov 18, 2026 | |
| $6.34 Nov 19, 2026 | $258M | 36 5-pillar Nov 18, 2026 | |
| $9.52 Nov 18, 2026 | $396M | 35 5-pillar Nov 18, 2026 | |
| $10.62 Nov 19, 2026 | $590M | 34 5-pillar Nov 18, 2026 | |
| $18.54 Nov 18, 2026 | $905M | 34 5-pillar Nov 18, 2026 | |
| Avita Medical (RCEL) — this page | $15.99 | $507M | 20 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $11.00 – $20.00
- Consensus target
- $14.33
- Median target
- $12.00
Consensus record · Captured .
Measured against a quoted price of $15.99 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 12, 2026
- Transactions
- 9
- Identified insiders
- 3
- Purchases
- 6
- Sales
- 0
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RCEL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RCEL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Avita Medical (RCEL)?
Investor Questions: RCEL Stock
These answers are editorial: 1 of these 9 answers is drawn from the RCEL research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RCEL?
RCEL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is RCEL a good stock to buy?
Stock Expert AI does not rate RCEL buy, sell or hold. Avita Medical Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RCEL stock price today?
The last price recorded for Avita Medical Inc. (RCEL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RCEL price target?
The analyst consensus price target for Avita Medical Inc. (RCEL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about RCEL stock?
Analyst coverage of AVITA Medical (RCEL) is limited, reflecting its small-cap status and focus on a niche market. Current sentiment is cautiously optimistic, with analysts noting the potential of the RECELL System and its expansion into new indications.
What are the key factors to evaluate for RCEL?
Avita Medical Inc. (RCEL) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. RECELL System is AVITA Medical's lead product, offering a novel approach to burn treatment using Spray-On Skin cells derived from the patient's own skin. Not financial advice.
How frequently does RCEL data refresh on this page?
RCEL's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RCEL's recent stock price performance?
Avita Medical Inc. (RCEL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RECELL System technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RCEL overvalued or undervalued right now?
Avita Medical Inc. (RCEL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com